Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Omer Shvili who wrote (169)	2/15/1998 1:58:00 PM
From: Doug	Respond to of 340

Thank you for that enlightening note. I do hope TEVA meets your expectations.

To: Omer Shvili who wrote (169)	3/26/1998 10:22:00 PM
From: Ariella	Read Replies (2) \| Respond to of 340

"Copaxone Slows Progression Of Disability, Reduces Relapses In MS" TORONTO, ON -- March 18, 1998 - Research published in the current issue of Neurology shows that Copaxone(R) (glatiramer acetate for injection) can actually slow the progression of relapse-remitting Multiple Sclerosis (MS). continued at link: pslgroup.com Question: is this "new" news or so old that no one cares? It seems to me that such research ought to help this drug gain market share. --Ariella